GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.24+0.24 (+12.00%)
Close on Nov 18, 2026Market cap $101.35MP/E –Yield –
Genelux revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Genelux's revenue for the twelve months ending Dec 31, 2024 was $8.00K, down 95.3% year over year. For fiscal 2025 it was $8.00K, up 0.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.00K | 0.0% |
| FY2024 | Dec 31, 2024 | $8.00K | -95.3% |
| FY2023 | Dec 31, 2023 | $170.00K | -98.5% |
| FY2022 | Dec 31, 2022 | $11.07M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $8.00K | -95.3% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $170.00K | – |
| Q4 FY2022 | Dec 31, 2022 | $68.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $11.00M | – |
See a number that looks wrong?